These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 36015225)

  • 1. Targeting Myocardial Fibrosis-A Magic Pill in Cardiovascular Medicine?
    Scridon A; Balan AI
    Pharmaceutics; 2022 Jul; 14(8):. PubMed ID: 36015225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioactive Compounds and Cardiac Fibrosis: Current Insight and Future Prospect.
    Majid A; Hassan FO; Hoque MM; Gbadegoye JO; Lebeche D
    J Cardiovasc Dev Dis; 2023 Jul; 10(7):. PubMed ID: 37504569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Innate Immunity Effector Cells as Inflammatory Drivers of Cardiac Fibrosis.
    Baci D; Bosi A; Parisi L; Buono G; Mortara L; Ambrosio G; Bruno A
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32998408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extracellular matrix remodeling and cardiac fibrosis.
    Li L; Zhao Q; Kong W
    Matrix Biol; 2018 Aug; 68-69():490-506. PubMed ID: 29371055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circular noncoding RNAs as potential therapies and circulating biomarkers for cardiovascular diseases.
    Bayoumi AS; Aonuma T; Teoh JP; Tang YL; Kim IM
    Acta Pharmacol Sin; 2018 Jul; 39(7):1100-1109. PubMed ID: 29565037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetics in Reactive and Reparative Cardiac Fibrogenesis: The Promise of Epigenetic Therapy.
    Ghosh AK; Rai R; Flevaris P; Vaughan DE
    J Cell Physiol; 2017 Aug; 232(8):1941-1956. PubMed ID: 27883184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Suppressing myocardial fibrosis to promote myocardial regeneration as a therapeutic strategy for chronic cardiovascular diseases].
    Mi S; Hu ZW
    Sheng Li Ke Xue Jin Zhan; 2010 Oct; 41(5):352-8. PubMed ID: 21416925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Featured Article: TGF-β1 dominates extracellular matrix rigidity for inducing differentiation of human cardiac fibroblasts to myofibroblasts.
    Cho N; Razipour SE; McCain ML
    Exp Biol Med (Maywood); 2018 Apr; 243(7):601-612. PubMed ID: 29504479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac fibrosis.
    Frangogiannis NG
    Cardiovasc Res; 2021 May; 117(6):1450-1488. PubMed ID: 33135058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Processes and Mechanisms of Cardiac and Pulmonary Fibrosis.
    Murtha LA; Schuliga MJ; Mabotuwana NS; Hardy SA; Waters DW; Burgess JK; Knight DA; Boyle AJ
    Front Physiol; 2017; 8():777. PubMed ID: 29075197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interplay between extracellular matrix components and cellular and molecular mechanisms in kidney fibrosis.
    Rayego-Mateos S; Campillo S; Rodrigues-Diez RR; Tejera-Muñoz A; Marquez-Exposito L; Goldschmeding R; Rodríguez-Puyol D; Calleros L; Ruiz-Ortega M
    Clin Sci (Lond); 2021 Aug; 135(16):1999-2029. PubMed ID: 34427291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the microRNA-34a as a Novel Therapeutic Strategy for Cardiovascular Diseases.
    Hua CC; Liu XM; Liang LR; Wang LF; Zhong JC
    Front Cardiovasc Med; 2021; 8():784044. PubMed ID: 35155600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Gut Microbiota as a Novel Strategy for Prevention and Treatment of Hypertension, Atrial Fibrillation and Heart Failure: Current Knowledge and Future Perspectives.
    Drapkina OM; Yafarova AA; Kaburova AN; Kiselev AR
    Biomedicines; 2022 Aug; 10(8):. PubMed ID: 36009566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural Compound Library Screening Identifies New Molecules for the Treatment of Cardiac Fibrosis and Diastolic Dysfunction.
    Schimmel K; Jung M; Foinquinos A; José GS; Beaumont J; Bock K; Grote-Levi L; Xiao K; Bär C; Pfanne A; Just A; Zimmer K; Ngoy S; López B; Ravassa S; Samolovac S; Janssen-Peters H; Remke J; Scherf K; Dangwal S; Piccoli MT; Kleemiss F; Kreutzer FP; Kenneweg F; Leonardy J; Hobuß L; Santer L; Do QT; Geffers R; Braesen JH; Schmitz J; Brandenberger C; Müller DN; Wilck N; Kaever V; Bähre H; Batkai S; Fiedler J; Alexander KM; Wertheim BM; Fisch S; Liao R; Diez J; González A; Thum T
    Circulation; 2020 Mar; 141(9):751-767. PubMed ID: 31948273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Traditional Chinese medicine as a therapeutic option for cardiac fibrosis: Pharmacology and mechanisms.
    Li X; Li L; Lei W; Chua HZ; Li Z; Huang X; Wang Q; Li N; Zhang H
    Biomed Pharmacother; 2021 Oct; 142():111979. PubMed ID: 34358754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic and Therapeutic Properties of Exosomes in Cardiac Fibrosis.
    Fan J; Ren M; He Y
    Front Cell Dev Biol; 2022; 10():931082. PubMed ID: 35859903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multifunctional biomaterial platforms for blocking the fibrosis process and promoting cellular restoring effects in myocardial fibrosis therapy.
    Yue T; Xiong S; Zheng D; Wang Y; Long P; Yang J; Danzeng D; Gao H; Wen X; Li X; Hou J
    Front Bioeng Biotechnol; 2022; 10():988683. PubMed ID: 36185428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of hepatic fibrosis: pathophysiological basis of antifibrotic therapies.
    Ismail MH; Pinzani M
    Hepat Med; 2011 Jul; 3():69-80. PubMed ID: 24367223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel therapeutic strategies targeting fibroblasts and fibrosis in heart disease.
    Gourdie RG; Dimmeler S; Kohl P
    Nat Rev Drug Discov; 2016 Sep; 15(9):620-638. PubMed ID: 27339799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac fibrosis in myocardial infarction-from repair and remodeling to regeneration.
    Talman V; Ruskoaho H
    Cell Tissue Res; 2016 Sep; 365(3):563-81. PubMed ID: 27324127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.